Scynexis to recall GSK-partnered antifungal from market (updated)

Scynexis

25/09/2023 13:55

(Adds background on drug throughout)
       Sept 25 (Reuters) - Drugmaker Scynexis  SCYX.O  said on
Monday it would voluntarily recall its antifungal drug
Brexafemme from the market and put a temporary hold on studies
of the therapy due to the potential risk of cross contamination
with another compound.  
    The company said it became aware that substances used to
make beta-lactam, which can cause allergic reactions in some
people, are manufactured using equipment common to the
manufacturing process for Brexafemme.
    British drugmaker GSK  GSK.L  has licensed the yeast
infection pill from Scynexis.
    Scynexis said the recall was cautionary and that it had not
received any report of any adverse events due to possible
beta-lactam cross contamination. 
    Up to 75% of women have at least one episode of vulvovaginal
candidiasis, commonly known as a vaginal yeast infection, in
their lifetimes, according to the U.S. Centers for Disease
Control and Prevention. 
    

 (Reporting by Manas Mishra in Bengaluru; Editing by Krishna
Chandra Eluri)
 ((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manaswrites15;))